Natriuretic peptides in heart failure: should therapy be guided by BNP levels?
暂无分享,去创建一个
[1] Naoto Minamino,et al. A new natriuretic peptide in porcine brain , 1988, Nature.
[2] Michael L. Johnson,et al. Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload , 2000, Hypertension.
[3] Moĭbenko Aa,et al. The heart as an endocrine organ , 1990 .
[4] O. Vuolteenaho,et al. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. , 1998, Annals of medicine.
[5] R. Doughty,et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.
[6] J. Cohn,et al. Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.
[7] S. Réhman,et al. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[8] A. Dobson,et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.
[9] D. Levy,et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. , 2002, The American journal of cardiology.
[10] Robert H Christenson,et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.
[11] Faquan Liang,et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.
[12] C. Frampton,et al. Abstract 5946: Ntprobnp Guided Treatment for Chronic Heart Failure: Results from the Battlescarred Trial , 2008 .
[13] E. Hartter,et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.
[14] Gabriel Thabut,et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.
[15] A. Ferreira,et al. N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.
[16] D. Lloyd‐Jones,et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. , 2006, Journal of the American College of Cardiology.
[17] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[18] C. Yancy,et al. Influence of hospital length of stay for heart failure on quality of care. , 2008, The American journal of cardiology.
[19] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[20] Douglas W Mahoney,et al. Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.
[21] M. Emi,et al. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. , 2007, Biochemical and biophysical research communications.
[22] D. Levy,et al. Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.
[23] H. S. Kim,et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Struthers,et al. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.
[25] J. Daubert,et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.
[26] N. Freemantle,et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. , 2008, Journal of the American College of Cardiology.
[27] L. Fisher,et al. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.
[28] J. P. Henry,et al. Evidence of the Atrial Location of Receptors Influencing Urine Flow , 1956, Circulation research.
[29] D. Levy,et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure , 2009, Nature Genetics.
[30] M. McCarthy,et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. , 2007, Human molecular genetics.
[31] Harlan M Krumholz,et al. ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.
[32] A. Cohen-Solal,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.
[33] R. Califf,et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. , 2005, American heart journal.
[34] K. Kugiyama,et al. Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.
[35] J. Rouleau,et al. Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.
[36] M. Cheitlin,et al. BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial , 2010 .
[37] Kenji Nakamura,et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[38] C. Yancy,et al. Use of aldosterone antagonists in heart failure. , 2009, JAMA.
[39] R. White,et al. Letter by Tang et al regarding article, "BIPHASIC trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest". , 2007, Circulation.
[40] M. Pfeffer,et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.
[41] G. Palade,et al. SPECIFIC GRANULES IN ATRIAL MUSCLE CELLS , 1964, The Journal of cell biology.
[42] A. D. de Bold,et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.
[43] R. Doughty,et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.
[44] J. Cohn,et al. Valsartan in heart failure trial (Val-HeFT) , 1998 .
[45] C. Frampton,et al. Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.
[46] A. Richards,et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. , 1993, British heart journal.
[47] M. Kinoshita,et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[48] P. Twomey,et al. Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. , 2007, Clinica chimica acta; international journal of clinical chemistry.